Rituximab (anti-CD20) adjunctive therapy for Opsoclonus-Myoclonus syndrome Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Immunologic Factors
  • Paraneoplastic Syndromes, Nervous System

abstract

  • Rituximab seems efficacious and safe as adjunctive therapy for OMS. Selective targeting of CSF B lymphocytes represents a novel and valuable paradigm shift in the therapy for centrally mediated paraneoplastic disorders.

publication date

  • September 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/01.mph.0000212991.64435.f0

PubMed ID

  • 17006265

Additional Document Info

start page

  • 585

end page

  • 93

volume

  • 28

number

  • 9